{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T18:09:30Z","timestamp":1781114970815,"version":"3.54.1"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Approximately 40% of diabetic macular edema (DME) cases are resistant to conventional anti-vascular endothelial growth factor (VEGF) therapy. Although faricimab (an antibody against VEGF-A and angiopoietin-2 [Ang-2]) has shown efficacy in treatment-na\u00efve DME, real-world evidence on switching strategies in resistant cases remains limited. We evaluated the 1\u2011year real\u2011world effectiveness of switching to faricimab in resistant DME and explored central choroidal thickness (CCT) changes and their relationship to retinal and choroidal responses. This retrospective study included 28 eyes from 19 patients with treatment-resistant DME who switched from aflibercept or ranibizumab to faricimab between May 2022 and August 2023. Central retinal thickness (CRT), CCT, best-corrected visual acuity (BCVA), and injection frequency were evaluated 1 year before, immediately before, and 1 year post-switching. Mean CRT significantly decreased from pre-switching levels of 453\u2009\u00b1\u2009112 \u03bcm to 322\u2009\u00b1\u200960 \u03bcm 1-year post-switching (28.9% reduction). The dry macula rate (CRT\u2009\u2264\u2009325 \u03bcm) was achieved in 53.6% of eyes at 1 year. Injection frequency was significantly higher in the year after switching than in the year before switching (3.5 vs. 5 injections). LogMAR BCVA showed no significant change (0.31\u2009\u00b1\u20090.27 vs. 0.34\u2009\u00b1\u20090.32). Ellipsoid zone (EZ)\/external limiting membrane (ELM) disruption increased from 28.6% at 1 year before switching to 35.7% immediately before switching, with minimal progression to 39.3% at 1 year post-switching. Mean CCT demonstrated no significant change (238\u2009\u00b1\u200982 \u03bcm vs. 230\u2009\u00b1\u200962 \u03bcm). Faricimab achieved significant anatomical improvements in resistant DME supporting its efficacy in real-world practice. Stable CCT may indicate preserved choroidal perfusion and represent a favorable characteristic of dual VEGF-A and Ang-2 inhibition. The potential suppression of the outer retinal structural deterioration may represent a marker of vascular health during chronic anti-VEGF therapy.<\/jats:p>","DOI":"10.1371\/journal.pone.0351168","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:34:04Z","timestamp":1781112844000},"page":"e0351168","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes after switching to faricimab in treatment-resistant diabetic macular edema: A 1-year observational study with choroidal thickness assessment"],"prefix":"10.1371","volume":"21","author":[{"given":"Ryo","family":"Tomemori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9966-2287","authenticated-orcid":true,"given":"Hidetsugu","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Kiriishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Omi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ohnaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"3","key":"pone.0351168.ref001","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"JWY Yau","year":"2012","journal-title":"Diabetes Care"},{"issue":"13","key":"pone.0351168.ref002","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"DA Antonetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0351168.ref003","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"QD Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"9","key":"pone.0351168.ref004","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","article-title":"Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab","volume":"130","author":"SB Bressler","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"pone.0351168.ref005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ophtha.2017.08.031","article-title":"OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant","volume":"125","author":"D Zur","year":"2018","journal-title":"Ophthalmology"},{"key":"pone.0351168.ref006","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2147\/OPTH.S100764","article-title":"Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials","volume":"10","author":"PU Dugel","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"pone.0351168.ref007","first-page":"1427","article-title":"An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy","volume":"9","author":"F Pacella","year":"2016","journal-title":"Int J Ophthalmol"},{"issue":"12","key":"pone.0351168.ref008","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.it.2006.10.004","article-title":"Angiopoietins: a link between angiogenesis and inflammation","volume":"27","author":"U Fiedler","year":"2006","journal-title":"Trends Immunol"},{"issue":"1","key":"pone.0351168.ref009","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00125-017-4435-8","article-title":"Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond","volume":"61","author":"H-P Hammes","year":"2018","journal-title":"Diabetologia"},{"key":"pone.0351168.ref010","doi-asserted-by":"crossref","first-page":"45081","DOI":"10.1038\/srep45081","article-title":"Elevated angiopoietin 2 in aqueous of patients with neovascular age related macular degeneration correlates with disease severity at presentation","volume":"7","author":"DS Ng","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"pone.0351168.ref011","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial","volume":"126","author":"J Sahni","year":"2019","journal-title":"Ophthalmology"},{"issue":"10326","key":"pone.0351168.ref012","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"CC Wykoff","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"pone.0351168.ref013","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10792-024-03226-2","article-title":"Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema","volume":"44","author":"F Pichi","year":"2024","journal-title":"Int Ophthalmol"},{"issue":"14","key":"pone.0351168.ref014","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1167\/iovs.65.14.46","article-title":"Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema","volume":"65","author":"KL Huber","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"pone.0351168.ref015","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/medicina60050732","article-title":"Treatment effects of switching to faricimab in eyes with diabetic macular edema refractory to aflibercept","volume":"60","author":"T Tatsumi","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"pone.0351168.ref016","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2147\/OPTH.S424314","article-title":"One year results of faricimab for aflibercept-resistant diabetic macular edema","volume":"17","author":"RB Rush","year":"2023","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"pone.0351168.ref017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1167\/iovs.11-8782","article-title":"Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography","volume":"53","author":"CS Tan","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"pone.0351168.ref018","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/IAE.0b013e31825db73d","article-title":"Macular and peripapillary choroidal thickness in diabetic patients","volume":"32","author":"S Vujosevic","year":"2012","journal-title":"Retina"},{"issue":"5","key":"pone.0351168.ref019","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1167\/iovs.12-11503","article-title":"Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients","volume":"54","author":"JT Kim","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"pone.0351168.ref020","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ajo.2014.08.001","article-title":"Three-dimensional automated choroidal volume assessment on standard spectral-domain optical coherence tomography and correlation with the level of diabetic macular edema","volume":"158","author":"BS Gerendas","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"pone.0351168.ref021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226630","article-title":"Relationship between diabetic macular edema and choroidal layer thickness","volume":"15","author":"H Endo","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"pone.0351168.ref022","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/IAE.0000000000000053","article-title":"Choroidal thickness in diabetic retinopathy: the influence of antiangiogenic therapy","volume":"34","author":"I La\u00edns","year":"2014","journal-title":"Retina"},{"issue":"4","key":"pone.0351168.ref023","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/15569527.2021.1949338","article-title":"Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results","volume":"40","author":"F Savur","year":"2021","journal-title":"Cutan Ocul Toxicol"},{"issue":"3","key":"pone.0351168.ref024","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/15569527.2024.2380325","article-title":"The effect of intravitreal anti-VEGF injections on choroidal vascular index in patients with diabetic macular edema","volume":"43","author":"A Toprak","year":"2024","journal-title":"Cutan Ocul Toxicol"},{"issue":"1","key":"pone.0351168.ref025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2014.09.033","article-title":"Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema","volume":"159","author":"N Rayess","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"pone.0351168.ref026","doi-asserted-by":"crossref","first-page":"13798","DOI":"10.1038\/s41598-024-63435-8","article-title":"Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema","volume":"14","author":"Y Saima","year":"2024","journal-title":"Sci Rep"},{"issue":"11","key":"pone.0351168.ref027","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema","volume":"132","author":"JK Sun","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"pone.0351168.ref028","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaophthalmol.2019.1963","article-title":"Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial","volume":"137","author":"NM Bressler","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"pone.0351168.ref029","article-title":"Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant","volume":"98","author":"D Zur","year":"2020","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"pone.0351168.ref030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrm2639","article-title":"Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system","volume":"10","author":"HG Augustin","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"pone.0351168.ref031","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway","volume":"16","author":"P Saharinen","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"6353","key":"pone.0351168.ref032","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal2379","article-title":"Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology","volume":"357","author":"HG Augustin","year":"2017","journal-title":"Science"},{"issue":"5","key":"pone.0351168.ref033","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"D Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"44","key":"pone.0351168.ref034","doi-asserted-by":"crossref","first-page":"18751","DOI":"10.1073\/pnas.0905010106","article-title":"An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris","volume":"106","author":"M Saint-Geniez","year":"2009","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:34:13Z","timestamp":1781112853000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351168"}},"subtitle":[],"editor":[{"given":"Daisuke","family":"Nagasato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0351168","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}